AbbVie Inc. · ABBV · Next earnings

AbbVie Inc. reports Wednesday, Feb 3, 2027

ABBV reports before market open with consensus EPS at $3.89 and revenue at $18.33B. Last quarter: AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth

Reports Before market open90 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $3.89 Calendar consensus
Consensus revenue $18.33B Calendar consensus
Report date Feb 3, 2027 Wednesday, date estimated
Session Before market open 90 days away

Where ABBV left off: FY2026 Q3

Full report

AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth

EPS surprise +2.4% Reported $3.82 vs $3.73
Revenue surprise +0.5% Reported $17.40B vs $17.32B
Stock move +1.4% Event window
Subsequent drift 0.0% Up to 20 sessions

Raised full-year revenue guidance by $200 million to $67.8 billion.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Continued biosimilar pressure on Humira sales.
  • Potential IRA pricing impact on Vraylar beginning in 2027.
  • Regulatory uncertainty around Boey and other pending submissions.
  • 340B program exposure and related rebate considerations.
  • Foreign-exchange headwinds affecting reported growth.

Questions analysts left open

  • Payer access and rebate concessions for immunology products.
  • Timing and magnitude of Skyrizi subcutaneous uptake.
  • Impact of IRA pricing on Vraylar revenue.
  • Progress of the 340B pilot and potential cost implications.
  • Readiness of pipeline readouts including etentamig, Epkinly, and Qulipta.

Ask FN2 about ABBV next report

Transcript, numbers and history already loaded
What should I watch for in ABBV's next earnings report?How did ABBV guide last quarter, and is consensus above or below that?Give me the bull and bear case going into ABBV earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the ABBV recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent ABBV quarters

All ABBV earnings
+1.4%FY2026 Q3-2.5%FY2026 Q2+3.1%FY2026 Q1-4.5%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.